gip/glp-1 PDB-101: Molecule of the Month: Incretins Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP)

The way to protect against this is adequate protein

Benefits of Lifelong Use Sustained appetite control and hunger reduction Continued prevention of weight regain Lower risk of obesity-related complications (e.g., diabetes, heart disease) Potential Challenges Ongoing injection therapy requirements Possible side effects such as gastrointestinal discomfort Access and insurance coverage variability Cost considerations (which your healthcare provider can help navigate) Alternatives and Complementary Supports For those exploring options beyond Wegovy, other GLP-1 receptor agonists or weight loss medications may be considered

They may recommend moving to the next dose sooner than planned

That doesnt just go away because the number on the scale changes